Abstract
Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Keywords: Alzheimer's disease, beta-amyloid, tau hyperphosphorylation, stroke, therapeutic strategy.
Current Alzheimer Research
Title:Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Volume: 13 Issue: 3
Author(s): Xian-Le Bu, Shu-Sheng Jiao, Yan Lian and Yan-Jiang Wang
Affiliation:
Keywords: Alzheimer's disease, beta-amyloid, tau hyperphosphorylation, stroke, therapeutic strategy.
Abstract: Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Bu Xian-Le, Jiao Shu-Sheng, Lian Yan and Wang Yan-Jiang, Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151215110114
DOI https://dx.doi.org/10.2174/1567205013666151215110114 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetics of Aging
Current Genomics Neural Stem Cells Transplanted in a Mouse Model of Parkinson’s Disease Differentiate to Neuronal Phenotypes and Reduce Rotational Deficit
CNS & Neurological Disorders - Drug Targets Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies HIV and Substance Abuse: A Commentary
Current HIV Research Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Severe Mental Disorders from a Cognitive-Behavioural Perspective: A Comprehensive Review from Conceptualization to Intervention
Current Psychiatry Reviews Sense and Sensibility When Prescribing ‘Off-Label’ to Psychiatric Patients
Current Pharmaceutical Design Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay
Current Computer-Aided Drug Design Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Anandamide Dysfunction in Prodromal and Established Psychosis
Current Pharmaceutical Design Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Rexinoids as Therapeutics for Alzheimer’s Disease: Role of APOE
Current Topics in Medicinal Chemistry Dance for People with Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology